March 27, 2024
Tentative Program

10:00:10:20 Enhanced bone healing under Immunomodulation
George M. Weisz, University of New South Wales, Australia
   
10:20:10:40 A potential therapeutic drug for osteoporosis: prospect for osteogenic LncRNAs
Fanjin Meng, North Sichuan Medical College, China
   
10:40:11:00 Development of an Intelligent Nomogram for Predicting Nonadherence to Biologic Treatment in Rheumatoid Arthritis Patients
Zige Liu, The First Affiliated Hospital of Guangxi Medical University, China
   
11:00:11:20 Tofacitinib versus Methotrexate as the First Line Disease-Modifying Antirheumatic Drugs in the Treatment of Rheumatoid Arthritis: an open-label random 
Mohammad Mamun Khan, Department of Rheumatology, Bangabandhu Sheikh Mujib Medical University, Bangladesh.
   
11:20:11:40 Evolution of biomarker research in autoimmunity conditions for health professionals and clinical practice: antibody-proteases as trans-lational tools designed to monitor autoimmune diseases at Clinical and Subclinical Stages
Sergey Suchkov, Precision Nutriciology & Biodesign of the Institute for Biotech & Global Health of RosBioTech, Russia
   
11:40:12:00 Altered BTLA expression and function in lupus T cells: consequences for therapeutic targeting
Fanny Monneaux, CNRS, Institut de Biologie Moléculaire et Cellulaire, Immunologie, Immunopathologie et Chimie Thérapeutique, Strasbourg, France 
   
12:00:12:10
Networking Break
   
12:10:12:30 Relationship between different anti-rheumatic drug therapies and complementary and alternative medicine in patients with rheumatoid arthritis: an interview based cross-sectional study
BEDOR A. ALOMARI, Department of Pharmaceutical Service, Prince Sultan Military Medical City, Riyadh, Saudi Arabia 
   
12:30:12:50 Current and novel immunotherapies for autoimmune disease with B-cell lineage targets: “B”-aware of secondary antibody deficiency 
Mohammed Yousuf Karim , Department of Pathology, Sidra Medicine, Doha, Qatar 
   
12:50:13:10 Functional Analysis of Autoantibody Signatures in Rheumatoid Arthritis 
Andreas Weinhäusel, AIT Austrian Institute of Technology GmbH, Austria
   
13:10:13:30 Antibodies against phosphorylcholine and protection in rheumatic diseases and other chronic inflammatory conditions
Johan Frostegård, IMM, Karolinska Institutet, Sweden
   
13:30:13:50 MTADV 5-MER peptide suppresses lung fibrosis ,RA, IBD and MS   mouse models and inhibits human fibroblasts biological functions by targeting SAA, which fuels fibrosis 
David Naor , The Lautenberg center of immunology and cancer research, faculty of medicine, Hebrew University of Jerusalem, Israel
   
13:50:14:10 The role of hydrogen sulfide in the analgesic effects of delta-opioid receptors during osteoarthritis pain in mice
Olga Pol, Autonomous University of Barcelona, Spain
14:10:14:20
Networking Break 
14:20:14:40 A novel loss-of-function mutation in LACC1 underlies hereditary juvenile arthritis with extended intra-familial phenotypic heterogeneity
Yonatan Butbul, Director of the Department of Pediatric Rheumatology and Pediatric Day Hospitalization at Rambam Hospital, Israel
   
14:40:15:00 Treatment of Experimental Autoimmune Encephalomyelitis with an Inhibitor of Phosphodiesterase-8 (PDE8)
Stefan Brocke, Immunology, UConn Health, USA
   
15:00:15:20 Galactose-Deficient IgA1 B cells in the Circulation of IgA Nephropathy Patients Carry Preferentially Lambda Light Chains and Mucosal Homing Receptors
Raska Milan, Dept. of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
   
15:20:15:40 Evidence for Bacterial Pathogenesis of Multiple Sclerosis in Humans
John Kriesel, University of Utah School of Medicine, Department of Internal Medicine, USA
   
15:40:16:00 Integrating digital inhalers into clinical care of patients with asthma and chronic obstructive pulmonary disease
Rajan K. Merchant, Allergy, Asthma, and Clinical Immunology Specialist , WCMG/DHMF/CSHRI/CSH, USA